OSI SYSTEMS INC annual report, FY2023

OSI Systems, Inc. Form 10-K Summary

Reporting period: Fiscal year ended June 30, 2023, filed August 29, 2023. The request metadata references “2022 Q4,” but the supplied filing is an annual report for fiscal 2023, including quarterly data for the quarter ended June 30, 2023.

Business Context

OSI Systems is a vertically integrated designer and manufacturer of specialized electronic systems and components for homeland security, healthcare, defense, aerospace and related markets. Its three reportable segments are Security, Healthcare, and Optoelectronics and Manufacturing.

Security: Security screening, inspection systems, software and turnkey screening services; 59% of fiscal 2023 consolidated revenue.
Healthcare: Patient monitoring, cardiology, remote monitoring and connected-care systems; 15% of consolidated revenue.
Optoelectronics and Manufacturing: Optoelectronic components, flexible circuits and electronics manufacturing services; 26% of consolidated revenue.

Financial Performance and Key Metrics

Metric	Fiscal 2023	Fiscal 2022	Change
Net revenue	$1,278.4 million	$1,183.2 million	+8.0%
Gross profit	$430.5 million	$424.4 million	+1.4%
Gross margin	33.7%	35.9%	Down 220 bps
Operating income	$135.3 million	$121.7 million	+11.1%
Operating margin	10.6%	10.3%	Up approximately 30 bps
Net income	$91.8 million	$115.3 million	Down 20.4%
Diluted EPS	$5.34	$6.45	Down 17.2%
Cash flow from operations	$94.8 million	$63.8 million	+48.6%

Net income declined primarily because fiscal 2022 included $27.4 million of other income from the sale of corporate-owned real estate, while fiscal 2023 had no comparable gain. Fiscal 2023 interest and other expense increased to $20.0 million from $9.0 million because of higher borrowing levels and interest rates following the retirement of the convertible notes.

Segment and Quarterly Trends

Security revenue: $760.3 million, up 14.6%, driven by higher product and service revenue, particularly cargo and vehicle inspection systems. Security operating income increased to $115.0 million from $98.8 million.
Healthcare revenue: $190.5 million, down 7.4%, reflecting lower patient monitoring and cardiology sales. Healthcare operating income fell to $11.4 million from $24.7 million.
Optoelectronics and Manufacturing revenue: $327.6 million, up 4.2%, with increases in optoelectronics and contract manufacturing. Operating income increased to $46.7 million from $45.0 million.
Fourth quarter fiscal 2023: Revenue was $411.9 million, gross profit was $143.0 million, operating income was $57.2 million, net income was $42.4 million and diluted EPS was $2.46. Fiscal 2022 fourth-quarter revenue and net income were $336.8 million and $33.8 million, respectively.

Cash Flow, Liquidity and Capital Structure

Cash and cash equivalents were $76.8 million at June 30, 2023, compared with $64.2 million at June 30, 2022.
Operating cash flow was $94.8 million. Investing cash outflow was $40.5 million, including $15.8 million of capital expenditures, $16.4 million for intangible and other assets, and $7.1 million for acquisitions.
Financing cash outflow was $37.2 million, including $34.7 million of share repurchases and $12.0 million of taxes paid on net share settlements, partially offset by net borrowing activity.
Total current and long-term debt was approximately $359.6 million at June 30, 2023, compared with $353.4 million a year earlier.
The $750 million senior secured credit facility included a $600 million revolving facility and a $150 million term loan. Outstanding borrowings were $215.0 million under the revolver and $143.1 million under the term loan; $48.5 million of letters of credit reduced availability. Total stated availability was $336.5 million.
The former 1.25% convertible notes were repurchased and cancelled in September 2022 using credit-facility borrowings.
Management stated that cash, operating cash flow and available credit are expected to fund operations for at least the next 12 months and the foreseeable future. The company was in compliance with its financial covenants at year-end.
Approximately 97% of cash was held by foreign subsidiaries and may be subject to repatriation tax considerations.

Material Changes Versus the Prior Comparable Period

Revenue growth accelerated to 8%, led by Security, while Healthcare declined and Optoelectronics and Manufacturing grew modestly.
Gross margin compressed from 35.9% to 33.7% due to product mix, higher component and raw-material costs, supply-chain pressures, and the lower-margin mix of the Optoelectronics and Manufacturing segment.
Operating margin improved despite lower gross margin because operating expenses declined by $7.4 million, principally from lower SG&A.
Interest expense increased materially after the convertible notes were replaced with higher-rate credit-facility borrowings.
Operating cash flow improved substantially, aided by lower inventory investment and higher accounts payable and other working-capital changes.
Backlog increased to approximately $1.8 billion at June 30, 2023 from $1.2 billion. Approximately $0.8 billion was not reasonably expected to be fulfilled in fiscal 2024.
The company completed four non-material acquisitions in fiscal 2023 and invested $46.7 million in share repurchases and related share-settlement taxes.

Outlook, Commentary, Risks and Unusual Items

Management cited two significant international Security contracts awarded during fiscal 2023 with aggregate value exceeding $700 million and revenue expected over multiple years.
Supply-chain disruption, labor availability, inflation, freight costs, component shortages and higher interest rates remain material pressures. Management expects continued uncertainty and stated that pricing and efficiency actions may not fully offset cost increases.
The Russia-Ukraine conflict increased geopolitical, supply-chain and cybersecurity risks. Certain Healthcare research and development activities in Ukraine were somewhat affected.
Foreign exchange movements reduced reported fiscal 2023 sales by approximately 1.0%. Management estimated that a 10% appreciation or depreciation of the U.S. dollar against relevant currencies would change operating income by approximately $13.5 million in the opposite direction.
Government customers may delay, reduce or terminate contracts, including for convenience. U.S. Government contracts are subject to procurement rules, security-clearance requirements and potential False Claims Act, suspension or debarment exposure.
The company received a February 2023 Department of Justice subpoena concerning a former employee and business dealings in Mexico since 2020. The company is cooperating and stated that no accrual was recorded because an adverse loss was not considered probable and reasonably estimable.
Potential future acquisition-related contingent payments had a maximum remaining amount of $55.3 million at year-end; the recorded contingent-consideration liability was $21.2 million.
Fiscal 2023 impairment, restructuring and other charges were $7.6 million, including $3.9 million of legal charges, $1.7 million of employee termination costs, $1.5 million of facility closure costs and $0.4 million of acquisition-related costs.
The company is implementing a company-wide ERP system and continues to integrate acquired businesses. Delays, cost overruns or control issues could disrupt operations and financial reporting.
The company reported no material information-security breaches during the prior three years, but identified cybersecurity, ransomware, privacy, product-liability, regulatory, environmental, litigation and international compliance risks.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. The critical audit matter concerned determining standalone selling prices for multiple performance obligations in Security-segment product contracts.

Most Important Facts for Investors to Verify

Whether the increased Security backlog converts to revenue and cash flow on the expected timetable, particularly the $0.8 billion not expected to be fulfilled in fiscal 2024.
Whether Security growth and operating leverage offset continued Healthcare weakness and margin pressure from components, labor, freight and inflation.
The sustainability of the 33.7% gross margin and the impact of product mix and supply-chain costs on future profitability.
Interest-rate exposure, revolver utilization, covenant headroom and the company’s ability to reduce or refinance approximately $359.6 million of debt.
The concentration and repatriation constraints associated with foreign-held cash, as well as foreign-exchange sensitivity.
The financial and operational implications of the Department of Justice subpoena, Mexico programs, legal proceedings and other contingencies.
Progress, cost and control implications of the ERP implementation and acquisition integration efforts.
Healthcare demand trends, regulatory clearances, EU Medical Devices Regulation compliance and reimbursement-driven pricing pressure.
Capital allocation priorities, including the remaining 1,721,870-share repurchase authorization and the absence of a dividend policy.